Impinduka mu mikorere ya za Gene zo mu bwoko bwa EML4-ALK zo mu bwoko bwa Human
Izina ry'igicuruzwa
HWTS-TM006-Human EML4-ALK Fusion Gene Mutation Detection Kit (Fluorescence PCR)
Icyemezo
TFDA
Ubumenyi bw'indwara
Iyi mashini ikoreshwa mu gupima ubwoko 12 bwa EML4-ALK fusion gene mu buryo bw'imiterere mu ngero z'abarwayi ba kanseri y'ibihaha itari iy'abantu mu buryo bwa vitro. Ibisubizo by'ibizamini ni ibyo kwifashisha mu buvuzi gusa kandi ntibigomba gukoreshwa nk'ishingiro ryonyine ryo kuvura abarwayi ku giti cyabo. Abaganga bagomba gufata ibyemezo birambuye ku bisubizo by'ibizamini hashingiwe ku bintu nk'uko umurwayi amerewe, ibimenyetso by'imiti, uko ubuvuzi buhagaze, n'ibindi bimenyetso by'ibizamini bya laboratwari. Kanseri y'ibihaha ni yo kanseri ikunze kugaragara cyane ku isi, kandi 80% ~ 85% by'abarwayi ni kanseri y'ibihaha itari iy'uturemangingo duto (NSCLC). Guhuza imiterere ya echinoderm microtubule-associated protein-like 4 (EML4) na anaplastic lymphoma kinase (ALK) ni intego nshya muri NSCLC, EML4 na ALK biherereye mu bantu, P21 na P23 bands kuri chromosome 2 kandi bitandukanyijwe n'imirongo igera kuri miliyoni 12.7 z'ibanze. Nibura ubwoko 20 bwo guhuza bwabonetse, muri bwo harimo ubwoko 12 bwa fusion mutants muri Table 1 busanzwe, aho mutant 1 (E13; A20) ari yo ikunze kugaragara cyane, ikurikirwa na mutants 3a na 3b (E6; A20), bungana na 33% na 29% by'abarwayi bafite EML4-ALK fusion gene NSCLC, uko bikurikirana. Ibikoresho bibuza ALK bihagarariwe na Crizotinib ni imiti igamije molecule nto yakozwe kugira ngo ikoreshwe mu guhindura gene fusion mutations za ALK. Binyuze mu kubuza imikorere y'akarere ka ALK tyrosine kinase, igahagarika inzira zayo zidasanzwe zo kumenyekanisha ibimenyetso, bityo ikabuza gukura kw'uturemangingo twa kanseri, kugira ngo igere ku buvuzi bwihariye ku ndwara za kanseri. Ubushakashatsi bwagaragaje ko Crizotinib ifite igipimo cyiza kirenga 61% ku barwayi bafite EML4-ALK fusion mutations, mu gihe nta ngaruka igira ku barwayi bo mu bwoko bwa wild-type. Kubwibyo, kumenya EML4-ALK fusion mutation ni ishingiro n'ishingiro ryo kuyobora ikoreshwa ry'imiti ya Crizotinib.
Umuyoboro
| FAM | Uburyo bwo kugabanya ingaruka ku mikorere 1, 2 |
| VIC (HEX) | Uburyo bwo kugabanya ingaruka ku mikorere ya 2 |
Ibipimo bya tekiniki
| Ububiko | ≤-18℃ |
| Igihe cyo kumara | Amezi 9 |
| Ubwoko bw'ingero | ingero z'ibice by'umubiri cyangwa ibice by'umubiri byashyizwemo parafini |
| CV | <5.0% |
| Ct | ≤38 |
| LoD | Iyi kit ishobora kubona impinduka za fusion kugeza kuri kopi 20. |
| Ibikoresho Bikoreshwa: | Sisitemu za PCR zikoreshwa mu gihe nyacyo 7500 Sisitemu za PCR zikoreshwa mu buryo bwihuse 7500 Sisitemu za PCR za SLAN ®-96P mu gihe nyacyo Sisitemu 5 za PCR za QuantStudio™ mu gihe nyacyo Sisitemu ya LightCycler®480 Real-Time PCR Sisitemu yo Gusuzuma PCR ya LineGene 9600 Plus mu gihe nyacyo MA-6000 Umuvuduko w'ubushyuhe mu gihe nyacyo Sisitemu ya BioRad CFX96 ya PCR mu gihe nyacyo Sisitemu ya BioRad CFX Opus 96 ya PCR mu gihe nyacyo |
Urugendo rw'akazi
Reagent isabwa gukurwamo: RNeasy FFPE Kit (73504) na QIAGEN, Ibice by'udusimba bya Parafini byakuwemo RNA yose (DP439) na Tiangen Biotech (Beijing) Co., Ltd.
